In this study, we observed schedule-dependent modulation of PMX cytotoxicity when combined with the HDACi MS275, which aligns with prior findings showing that HDAC inhibitors like Givinostat can reverse PMX resistance in NSCLC cell lines, regardless of p53 status52,53. Here, HDAC9 is linked to non-small cell lung carcinoma.